ParagonRx appoints new chief medical officer
Sep 02, 2013 (MarketLine via COMTEX) --
ParagonRx has announced the appointment of Stephen Sun as the new chief medical officer advising clients on regulatory and safety issues.
Dr. Sun, formerly with the U.S. Food and Drug Administration (FDA), will be reporting directly to ParagonRx President Jeffrey Fetterman.
"The focus today is on enhanced pharmacovigilance, putting preventions in place before any regulatory body requires it," Fetterman said. "Dr Sun's FDA experience will enrich the guidance we offer clients to assure that active risk management is at the core of developing all new products and services."
Dr Sun then transitioned to work for the pharmaceutical industry, first at Organon in Drug Safety and Medical Knowledge Management. He next joined Alpharma as Director of Drug Safety, managing the team responsible for adverse events, product complaints and medical information for all US generic and branded drugs. He was soon promoted to Senior Director of Medical Affairs, where he oversaw Phase I, II and IV clinical studies, risk management plans, pharmacovigilance, medical education, scientific publications, government affairs, health outcomes, and supported sales and marketing teams as well as working with medical science liaisons.
After King Pharmaceuticals' acquisition of Alpharma, Dr Sun served as King's Senior Director of Pharmacovigilance and Risk Management before moving on to further expand his industry experience in over-the-counter medications at Reckitt-Benckiser. With an interest in public health, Dr Sun joined the FDA as a Medical Officer. He has served in the CDER Division of Risk Management and most recently in the Controlled Substances Staff.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]